SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...
RAS-mutated mCRC, Clinical Data from ONSEMBLE Trial, and preclinical Data presented at AACR, demonstrated strong efficacy signal in bev na¯ve patients and support ongoing first-line RAS-mutated...
- Management will hold a conference call on Thursday, May 2 at 4:30 p.m. ET/1:30 p.m. PT - SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a...
RAS-mutated mCRC “ In RAS-mutated mCRC, novel preclinical finding demonstrates onvansertib inhibits the tumor's ability to adapt to hypoxia resulting in a significant decrease in both tumor...
Cardiff Announces Upcoming Presentations at the AACR Annual Meeting 2024
Cardiff Oncology’s PLK1 inhibitor showed hints of efficacy in a shelved Phase II test in second-line colorectal cancer, boosting Cardiff’s share price ahead of an upcoming readout in the frontline setting.
Cardiff Oncology Announces First Patient Dosed in Randomized First-line CRDF-004
Cardiff Oncology Provides Update on Ph 2 Randomized Second-line ONSEMBLE Trial
Cardiff Oncology Reports Fourth Quarter and Full Year 2023 Results